Insider trade

Officer sold ~$167K of BDX shares in the open market

Traded Jun 10, 2026 · Filed Jun 11, 2026

~$167K
Reported value · 1,100 sh @ $151.48: 14K
Holds after · shares reported: +20.5%
stock since the trade · S&P 500 +5.3%, $147.79 → $178.07 on Oct 1

Why it stands out

Becton Dickinson's & Pres Med.Essntl&BioPharm sold $167K of Becton Dickinson shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 10, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 11, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$166,628

Shares × reported transaction price

Timing vs results

34 days after results of May 7, 2026, 57 days before results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $147.79 on Jun 10, 2026, within 4% of its 52-week low, after a 1% drop over the previous 30 trading days

52-week range $142.35 (May 18, 2026) to $210.02 (Feb 6, 2026), 8% of the way up, from 251 adjusted closes. 30 trading days earlier: $149.52 on Apr 28, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	-3.8%	+0.4%	-4.1%
30 days	+5.2%	+1.0%	+4.2%
90 days	+20.6%	+2.2%	+18.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001628280-26-042571
Filed / recorded: Jun 11, 2026, 9:21 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BECTON DICKINSON & CO
Issuer CIK: 10795
Ticker: BDX
Reporting person: Michael David Garrison
Relationship: Officer
Officer title: EVP & Pres Med.Essntl&BioPharm
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jun 10, 2026
Transaction code: S
Shares / units: 1,100
Price per share: $151.48
Acquired / disposed: Disposed (D)
Shares owned after: 14,272
Ownership form: Direct
Amendment: No

Footnotes from the filing

Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.